NRAS and acute myeloid leukemia: Another study that employed whole exome sequencing (WES) on AML patient samples before and after crenolanib treatment to investigate resistance mechanisms found that this FLT3 inhibitor induced mutations in NRAS and IDH2 genes, which activate alternative signaling pathways [58].